|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug. Shares in Novo Nordisk rose almost 3 percent in early trading on Thursday, after the panel late on Wednesday concluded semaglutide is effective, reasonably safe and should be approved by the FDA. The panel voted 16-0 with one abstention in favor of the drug being approved.
Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA typically follows the recommendations of its advisors. Novo Nordisk is hoping that semaglutide, administered through a once-weekly injection, will take market share from Eli Lilly & Co's once-weekly Trulicity, which in turn has been taking share from Novo Nordisk's once-daily Victoza.
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
In 1H17, Eli Lilly's (LLY) Cymbalta reported revenues of around $381.2 million, compared with $435.2 million in 1H16.
Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
In 1H17, Eli Lilly’s (LLY) Humalog reported revenues of around $1.39 million, compared with $1.31 million in 1H16.
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
In 1H17, Eli Lilly's (LLY) Basaglar generated revenues of around $132.6 million, compared with $27.2 million in 1H16.
U.S. drugmaker Eli Lilly and Co said on Wednesday it will collaborate with CureVac AG on development of up to five immunotherapy cancer vaccines using the German company's messenger RNA (mRNA) technology. Under terms of the deal, CureVac will receive $50 million up front and Lilly will take an equity stake in CureVac worth about $53 million (45 million euros).
U.S. President Donald Trump is leaning toward naming former pharmaceutical industry executive Alex Azar as his pick to lead the Department of Health and Human Services, Politico reported on Tuesday, citing ...
The drug, dupilumab, was statistically significant in improving the ability to swallow in adults with moderate-to-severe eosinophilic esophagitis, when compared with a placebo. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the pipe that connects the throat and the stomach, and can lead to food getting stuck in the oesophagus and difficulties in swallowing.
Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.
Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.
In 2Q17, Sanofi’s (SNY) Consumer Healthcare business reported revenues of 1.2 billion euros, which is a 42.5% YoY rise on a CER basis and a YoY fall of 0.10% on a CER and CS basis.
Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study. The drug, dupilumab, was statistically significant in improving the ability to swallow in adults with moderate-to-severe eosinophilic esophagitis, when compared with a placebo. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the pipe that connects the throat and the stomach, and can lead to food getting stuck in the esophagus and difficulties in swallowing.
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.